ArticleTranslational psychiatry2026
taVNS alleviates depressive-like and metabolic dysfunction in T2DD mice with modulation of hypothalamic 5-HT signaling.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus and depression are mutually reinforcing, yet combined pharmacotherapy is limited by side effects and poor tolerability. Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulatory approach with emerging metabolic and antidepressant potential, although its central mechanisms remain unclear. Here, we investigated whether hypothalamic serotonergic signaling is involved in the dual effects of taVNS in a mouse model of type 2 diabetes with depression (T2DD). T2DD was induced in db/db mice by chronic unpredictable mild stress, followed by taVNS intervention (2/15 Hz, 1 mA, 30 min/day for 3 weeks). Behavioral performance, body weight, and fasting blood glucose were assessed, while brain-wide neuronal activity was mapped using fluorescence micro-optical sectioning tomography (fMOST). Hypothalamic 5-HT release was monitored by fiber photometry, and 5-HT content and 5-HT₁A receptor expression were quantified by ELISA and Western blotting. TaVNS significantly reduced body weight and fasting blood glucose, alleviated depression-like behaviors, and improved locomotor activity. Brain-wide mapping revealed state-dependent modulation of neuronal activity, characterized by widespread activation under physiological conditions and suppression of stress-induced hyperactivation in T2DD. Notably, taVNS induced robust hypothalamic 5-HT release, increased long-term 5-HT levels, and upregulated 5-HT₁A receptor expression. Correlation analyses further linked enhanced hypothalamic serotonergic signaling to improved glycemic control and behavioral outcomes. These findings suggest that hypothalamic 5-HT signaling may contribute to the dual metabolic and antidepressant effects of taVNS and highlight its potential as an integrative neuromodulatory intervention for metabolic-psychiatric comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.